Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Schering-Plough Asmanex Clears FDA; Manufacturing Will Begin This Fall

  • News

Executive Summary

Schering-Plough will not launch the newly approved asthma therapy Asmanex (mometasone furoate inhalation powder) before autumn

You may also be interested in...



Schering/Novartis To Develop Once-Daily Inhalation Combination For Asthma, COPD

Fixed-dose therapy will combine Novartis' investigational beta2-agonist indacaterol with Schering-Plough's Asmanex.

Schering Looking To Expand Therapeutic Frontiers Beyond Cholesterol

Schering-Plough is positioning itself to branch out from its cholesterol base into other therapeutic areas, CEO Fred Hassan said at the Morgan Stanley CEOs Unplugged investor conference on Jan. 4

Schering Looking To Expand Therapeutic Frontiers Beyond Cholesterol

Schering-Plough is positioning itself to branch out from its cholesterol base into other therapeutic areas, CEO Fred Hassan said at the Morgan Stanley CEOs Unplugged investor conference on Jan. 4

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS045619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By